IFRX

Latest News Updates

17:05

IFRX--%

InflaRx shares surge 13.13% after-hours as Raymond James raises price target to $9 on positive HS trial data.

11:43

IFRX--%

InflaRx shares jump 20.87% intraday after Raymond James and Cantor Fitzgerald raise price targets on positive HS trial data.

10:22

IFRX--%

InflaRx shares surge 10.13% intraday as INF904 shows significant improvement in HS and CSU clinical trials.

05:06

IFRX--%

InflaRx shares surge 43.09% premarket after positive Phase 2a data for INF904 in HS and CSU show strong efficacy and safety.

02:09

IFRX--%

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative and Chronic Spontaneous Urticaria

Monday Nov 10, 2025

21:20

IFRX--%

InflaRx Reports Promising Phase 2a Results for INF904, Faces Financial Challenges

18:09

IFRX--%

InflaRx shares surge 30.08% after-hours on positive Phase 2a INF904 data for HS and CSU.

17:52

IFRX--%

InflaRx shares surge 28.46% after-hours on positive Phase 2a INF904 data for HS and CSU.

16:11

IFRX--%

InflaRx Q3 Sales Down, Net Loss Narrows to €12.26M InflaRx Q3 Sales Down, Net Loss Narrows to €12.26M

16:03

IFRX--%

InflaRx shares surge 63.41% after-hours after positive INF904 Phase 2a data in HS and CSU drive investor optimism.

14:43

IFRX--%

InflaRx Announces Topline Phase 2a Data for INF904 in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa

10:42

IFRX--%

It looks like you sent an empty JSON object. Could you please clarify your question or provide more details about what you need help with? I'm here to assist.

10:27

IFRX--%

It seems like your message might be incomplete or empty. Could you please provide more details or clarify what you're asking for? I'm here to help with any questions or tasks you have! .

08:51

IFRX--%

+3

Top Pre-Market Stocks: IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS

08:18

IFRX--%

InflaRx: Guggenheim Maintains Buy Rating, Raises PT to $22 from $10

08:03

IFRX--%

InflaRx shares surge 86.99% premarket after positive Phase 2a data for INF904 in HS and CSU trials.

07:58

IFRX--%

InflaRx shares surge 73.17% premarket after positive Phase 2a INF904 data for HS and CSU.

07:54

IFRX--%

InflaRx shares surge 67.48% premarket on positive Phase 2a data for INF904 in HS and CSU.

07:34

IFRX--%

InflaRx's INF904 shows promise as immunomodulatory agent with biologic-like efficacy.

06:07

IFRX--%

InflaRx shares surge 28.46% premarket amid anticipation of Phase 2a INF904 trial results and Q3 financials release.